VANI on Nasdaq

Vivani Medical, Inc.

American electromedical and electrotherapeutic apparatus company. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with ADM TRONICS UNLIMITED, INC., Neuraxis, INC or Hongchang International Co., Ltd, or pick any stock.

  • TickerVANI on Nasdaq2
  • IndustryElectromedical & Electrotherapeutic Apparatus2
  • HeadquartersEmeryville, United States2
  • Incorporated inDE3
  • Business address1350 S. Loop Road, Alameda, Ca 945023
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formFor-Profit Corporation General Stock2
  • LEI5299004VTNX49EZIFL052
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered address5858 HORTON STREET, 94608 Emeryville, United States2
  • Registered withSecretary of State, 25367442

See how the biggest companies compare on our leaderboards

Vivani Medical, Inc. (“Vivani,” the “Company,” “we,” “us,” “our” or similar terms) is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal™ technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address leading causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-169.2%Return on equity5
-$25.5MFree cash flow5

Financial statements

Revenue675$0 in 2025
0$1.0M$2.0M$3.0M$4.0M2019: $3.4M$3.4M20192024: $0$020242025: $0$02025
Gross profit68$130.0K in 2021−89% since 2019
0$500.0K$1.0M$1.5M2019: $1.2M$1.2M20192020: $500.0K$500.0K2020−59%2021: $130.0K$130.0K2021−74%
Operating income6891075-$27.6M in 2025−19% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$34.0M-$34.0M20192020: -$14.9M-$14.9M2020−56%2021: -$13.3M-$13.3M2021−11%2022: -$21.2M-$21.2M2022+59%2023: -$27.0M-$27.0M2023+27%2024: -$24.7M-$24.7M2024−8%2025: -$27.6M-$27.6M2025+12%
Net income6891075-$26.6M in 2025−21% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$33.6M-$33.6M20192020: -$14.9M-$14.9M2020−56%2021: -$12.8M-$12.8M2021−14%2022: -$13.9M-$13.9M2022+9%2023: -$25.7M-$25.7M2023+85%2024: -$23.5M-$23.5M2024−8%2025: -$26.6M-$26.6M2025+13%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Research and development, net of grants$18.1M$15.7M
General and administrative, net of grants$9.4M$8.9M
Total operating expenses$27.6M$24.7M
Loss from operations-$27.6M-$24.7M
Other income, net$947.0K$1.2M
Net loss-$26.6M-$23.5M
Net loss per common share - basic (in dollars per share)-$0.43-$0.43
Net loss per common share - diluted (in dollars per share)-$0.43-$0.43
Weighted average shares outstanding - basic (in shares)62.4M shares55.0M shares
Weighted average shares outstanding - diluted (in shares)62.4M shares55.0M shares

Compare Vivani Medical, Inc. with another company

Leadership

Who has led Vivani Medical, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jonathan Will McGuire2015–2020
  2. Scott Dunbar2021
  3. Adam Mendelsohn2022–now

Chief financial officer

  1. Thomas B. Miller2014–2018
  2. Brigid Makes2022–2025
  3. Anthony Baldor2025–now

Chief operating officer

  1. William Patrick Ryan2018–2020
  2. Truc Le2022–2023
201520202025
Board members and other officers (23)

Former names

  • SECOND SIGHT MEDICAL PRODUCTS INCMay 2, 2006 to Aug 18, 20223
  • SECOUND SIGHT MEDICAL PRODUCTS INCOct 10, 2003 to Oct 10, 20033

Timeline

  1. Aug 31, 2022New chief executive Adam Mendelsohn becomes CEO13
  2. Apr 8, 2021New chief executive Scott Dunbar becomes CEO14
  3. Aug 24, 2015New chief executive Jonathan Will McGuire becomes CEO15

Filings

297 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 70 major events, 156 insider forms, 7 large holders, 43 other. The latest 20:

  1. Sep 25, 2026424B5 EDGAR
  2. Sep 16, 20268-K EDGAR
  3. Aug 17, 20268-K EDGAR
  4. Aug 13, 20268-K EDGAR
  5. Aug 13, 202610-Q EDGAR
  6. Aug 6, 20268-K EDGAR
  7. Jul 30, 20264 PRIMARY DOCUMENT EDGAR
  8. Jul 30, 20264 PRIMARY DOCUMENT EDGAR
  9. Jul 30, 20264 PRIMARY DOCUMENT EDGAR
  10. Jul 30, 20264 PRIMARY DOCUMENT EDGAR
  11. Jul 30, 20264 PRIMARY DOCUMENT EDGAR
  12. Jul 28, 20264 PRIMARY DOCUMENT EDGAR
  13. Jul 16, 20264 PRIMARY DOCUMENT EDGAR
  14. Jul 16, 20268-K EDGAR
  15. Jul 7, 20268-K EDGAR
  16. Jun 30, 20268-K EDGAR
  17. Jun 26, 20264 PRIMARY DOCUMENT EDGAR
  18. Jun 26, 20263 PRIMARY DOCUMENT EDGAR
  19. Jun 25, 20264 PRIMARY DOCUMENT EDGAR
  20. Jun 25, 20264 PRIMARY DOCUMENT EDGAR

The 297 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

133 open-market trades by officers, directors and large owners since October 2021: 133 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 15, 2026Williams GreggDirectorBuy793,650$1.26$1.0MForm 4
Jun 15, 2026Williams GreggDirectorBuy1,587,301$1.26$2.0MForm 4
May 15, 2026Williams GreggDirectorBuy1,587,301$1.26$2.0MForm 4
Apr 15, 2026Williams GreggDirectorBuy1,587,301$1.26$2.0MForm 4
Mar 15, 2026Williams GreggDirectorBuy1,575,231$1.07$1.7MForm 4
Feb 15, 2026Williams GreggDirectorBuy1,866,492$1.06$2.0MForm 4
Jan 27, 2026Williams GreggDirectorBuy1,351,351$1.48$2.0MForm 4
Jan 15, 2026Williams GreggDirectorBuy1,737,765$1.14$2.0MForm 4
Dec 29, 2025Mendelsohn AaronDirectorBuy20,000$1.23$24.6KForm 4
Dec 15, 2025Williams GreggDirectorBuy1,737,765$1.14$2.0MForm 4
Nov 15, 2025Williams GreggDirectorBuy1,737,764$1.14$2.0MForm 4
Oct 27, 2025Williams GreggDirectorBuy3,703,703$1.62$6.0MForm 4
Oct 15, 2025Williams GreggDirectorBuy1,737,764$1.14$2.0MForm 4
Sep 15, 2025Williams GreggDirectorBuy2,068,453$1.16$2.4MForm 4
May 16, 2025Williams GreggDirectorBuy2,405$1.01$2.4KForm 4
May 15, 2025Williams GreggDirectorBuy6,836$1.01$6.9KForm 4
May 14, 2025Williams GreggDirectorBuy3,499$1.01$3.5KForm 4
Apr 24, 2025Williams GreggDirectorBuy1,113$1.01$1.1KForm 4
Apr 22, 2025Williams GreggDirectorBuy243$1.01$245Form 4
Apr 21, 2025Williams GreggDirectorBuy1,569$1.01$1.6KForm 4

All 133 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 39. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC1,768,077$2.2M0.0%+237,144
Tanager Wealth Management LLP607,276$753.0K0.1%−33,809
Geode Capital Management, LLC587,745$728.9K0.0%−12,833
Tudor Investment Corp Et Al410,902$509.5K0.0%−15,400
Commonwealth Equity Services, LLC330,565$409.9K0.0%No change
Vanguard Fiduciary Trust Co325,462$403.6K0.0%+61,631
BlackRock, Inc.301,828$374.3K0.0%+4,330
Monetary Management Group Inc193,977$240.5K0.0%No change
State Street Corp154,965$192.2K0.0%No change
Northern Trust Corp116,907$145.0K0.0%+20,446
MAI Capital Management99,870$123.8K0.0%New
UBS Group AG51,108$63.4K0.0%−286,641
Armstrong Advisory Group, Inc45,000$55.8K0.0%−20,000
XTX Topco Ltd31,298$38.8K0.0%+20,604
Susquehanna International Group, Llp28,346$35.1K0.0%−57,940
Vanguard Global Advisers, LLC16,279$20.2K0.0%No change
StoneX Group Inc.14,143$18.6K0.0%New
Kestra Private Wealth Services, LLC12,216$15.1K0.0%No change
Headlands Technologies LLC11,271$14.0K0.0%New
Marshall Wace, Llp11,161$13.8K0.0%−81,108
Lazari Capital Management, Inc.10,000$12.4K0.0%No change
Jpmorgan Chase & Co3,389$4.1K0.0%−102
Tower Research Capital LLC (TRC)3,024$3.8K0.0%+427
Steward Partners Investment Advisory, LLC2,000$2.5K0.0%No change
SBI Securities Co., Ltd.1,164$1.4K0.0%−833

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46